The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 6-9 October 2014. Topics discussed at the meeting:
- PRAC recommends strengthening the restrictions on the use of valproate in women and girls
- PRAC review does not confirm increase in heart problems with testosterone medicines
- PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
- Five days left to respond to the consultation on public hearings
Read PRAC's monthly report from the meeting 6-9 October 2014